7Baggers

We provide you with 20 years of free, institutional-grade data for BCYC stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BCYC. Explore the full financial landscape of BCYC stock.

Reported DateCIKTickerType
2024-02-201761612BCYC10-KUrl
2023-11-021761612BCYC10-QUrl
2023-08-031761612BCYC10-QUrl
2023-05-041761612BCYC10-QUrl
2023-02-281761612BCYC10-KUrl
2022-11-031761612BCYC10-QUrl
2022-08-041761612BCYC10-QUrl
2022-05-051761612BCYC10-QUrl
2022-03-011761612BCYC10-KUrl
2021-11-041761612BCYC10-QUrl
2021-08-051761612BCYC10-QUrl
2021-05-061761612BCYC10-QUrl
2021-03-111761612BCYC10-KUrl
2020-11-051761612BCYC10-QUrl
2020-08-051761612BCYC10-QUrl
2020-05-071761612BCYC10-QUrl
2020-03-101761612BCYC10-KUrl
2019-11-071761612BCYC10-QUrl
2019-08-081761612BCYC10-QUrl
2019-04-261761612BCYCS-1Url

Bicycle Therapeutics plc
(NASDAQ:BCYC) 

BCYC stock logo

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express...

Founded: 2009
IPO Price: $14 (May 23, 2019)
Full Time Employees: 81
CEO: Kevin Lee  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about BCYC stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.